Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States

作者
Reema Mody,William J. Valentine,Meredith M. Hoog,Helen Sharland,Mark A. Belger
出处
期刊:Journal of managed care & specialty pharmacy [AMCP]
卷期号:30 (2): 153-162 被引量:11
标识
DOI:10.18553/jmcp.2024.30.2.153
摘要

BACKGROUND: Tirzepatide is a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for type 2 diabetes (T2D) treatment. OBJECTIVE: To compare the long-term cost-effectiveness of tirzepatide 10 mg and 15 mg vs semaglutide 2.0 mg, an injectable glucagon-like peptide-1 receptor agonist, in patients with T2D from a US health care payer perspective. METHODS: The PRIME T2D Model was used to project clinical and cost outcomes over a 50-year time horizon. Baseline cohort characteristics and treatment effects were sourced from a published adjusted indirect treatment comparison that used data from the SURPASS-2 and SUSTAIN FORTE trials. Patients were assumed to intensify to insulin therapy at a hemoglobin A1c of greater than 7.5%. Costs and health state utilities were derived from published sources. Future costs and clinical benefits were discounted at 3% annually. RESULTS: Tirzepatide 10 mg and 15 mg were associated with improved quality-adjusted life-expectancy (10 mg: 0.085 quality-adjusted life-years [QALYs], 15 mg: 0.121 QALYs), higher direct costs (10 mg: USD 5,990, 15 mg: USD 6,617), and incremental cost-effectiveness ratios of USD 70,147 and 54,699 per QALY gained, respectively, vs semaglutide 2.0 mg. Both doses of tirzepatide remained cost-effective vs semaglutide 2.0 mg over a range of sensitivity analyses. CONCLUSIONS: Long-term projections using the PRIME T2D model and based on treatment effects from an adjusted indirect treatment comparison indicate that tirzepatide 10 mg and 15 mg are likely to be cost-effective vs semaglutide 2.0 mg for the treatment of T2D in the United States.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
VirSnorlax完成签到,获得积分10
刚刚
書生途完成签到 ,获得积分10
2秒前
luoshiyi完成签到,获得积分10
2秒前
科研通AI6.3的应助被海盗船长采纳,获得10
3秒前
hhjguh的应助被Annora采纳,获得20
3秒前
徐XU发布了新的文献求助10
5秒前
今后的应助被Annora采纳,获得10
5秒前
慕青的应助被baiyi采纳,获得10
5秒前
6秒前
慕青的应助被小熊维尼采纳,获得10
6秒前
YiYang完成签到 ,获得积分10
7秒前
aaa发布了新的文献求助10
7秒前
8秒前
9秒前
9秒前
10秒前
10秒前
路特西兰完成签到,获得积分20
10秒前
无花果的应助被科研通管家采纳,获得30
11秒前
英俊的铭的应助被科研通管家采纳,获得10
11秒前
Ling完成签到,获得积分20
11秒前
CodeCraft的应助被科研通管家采纳,获得10
11秒前
Rony发布了新的文献求助10
11秒前
11秒前
酷波er的应助被科研通管家采纳,获得10
11秒前
DeepSeek的应助被科研通管家采纳,获得10
12秒前
bkagyin的应助被科研通管家采纳,获得10
12秒前
DOC_XIONG的应助被科研通管家采纳,获得10
12秒前
思源的应助被科研通管家采纳,获得20
12秒前
安详的惜梦完成签到 ,获得积分10
12秒前
英姑的应助被科研通管家采纳,获得10
13秒前
天天快乐的应助被科研通管家采纳,获得10
13秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
13秒前
Lny的应助被dawn采纳,获得10
13秒前
雨雨雨完成签到,获得积分20
13秒前
英俊的铭的应助被科研通管家采纳,获得10
13秒前
Lucas的应助被科研通管家采纳,获得10
13秒前
小马甲的应助被科研通管家采纳,获得30
13秒前
大个的应助被科研通管家采纳,获得10
13秒前
华仔的应助被科研通管家采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186382
求助须知:如何正确求助?哪些是违规求助? 9574807
关于积分的说明 21838252
捐赠科研通 7784045
什么是DOI,文献DOI怎么找? 3434752
关于科研通互助平台的介绍 2559164
邀请新用户注册赠送积分活动 2481535